Differential Proteome Profiling Using iTRAQ in Microalbuminuric and Normoalbuminuric Type 2 Diabetic Patients

Table 1

Clinical characteristics of normoalbuminuric (NA) and microalbuminuric (MA) type 2 diabetic patients.

Characteristics	NA 1^a	MA 1^a	NA 2^b	MA 2^b	NA 3^c	MA 3^c	NA 4^d	MA 4^d
	(𝑛=9)	(𝑛=9)	(𝑛=9)	(𝑛=9)	(𝑛=9)	(𝑛=9)	(𝑛=16)	(𝑛=16)
Gender (M/F)	4/5	5/4	5/4	4/5	5/4	4/5	9/7	9/7
Mean age (years)	62.4±8.0; (49–72)	66.4±7.8; (55–82)	60.7±4.7; (54–67)	61.9±2.7; (56–65)	64.9±5.3; (56–73)	62.3±4.4; (41–72)	63.7±7.5; (49–72)	63.2±9.8; (44–82)
Duration of diabetes (years)	9.1±4.4	10.4±7.0	8.7±5.0	7.3±4.7	13.0±9.0	10.6±7.7	9.9±4.8	11.6±7.3
BMI (kg/m^2)	25.4±3.0	24.9±3.3	23.8±2.1	24.9±3.6	23.1±2.7	22.6±2.6	24.4±2.9	25.1±2.9
Fasting plasma glucose (mg/dL)	130.8±21.1	133.8±36.4	131.3±31.9	135.8±41.3	117.8±21.7	117.6±26.6	132.4±19.2	144.8±35.7
HbA1C (%)	6.8±0.7	6.8±0.9	6.9±0.7	7.4±0.8	7.2±0.7	7.2±0.7	6.8±0.6	7.0±0.8
Blood urea nitrogen (mg/dL)	15.1±4.8	17.1±4.9	13.8±2.4	15.7±3.9	16.8±3.4	17.7±4.4	15.1±3.9	16.4±4.1
Serum creatinine (mg/dL)	1.0±0.1	1.1±0.2	0.9±0.2	1.0±0.1	1.0±0.2	1.0±0.2	0.98±0.13	1.0±0.15
Serum total cholesterol (mg/dL)	184.4±34.5	180.6±29.1	164.2±25.5	165.6±24.5	164.9±22.2	175.4±50.7	181.5±29.7	182.1±25.5
Serum HDL cholesterol (mg/dL)	48.1±12.2	46.1±8.8	52.3±9.5	48.9±8.3	55.0±7.8	41.5±4.7	46.4±10.8	46.8±7.7
Serum LDL cholesterol (mg/dL)	99.8±26.6	102.6±22.3	91.0±21.6	92.0±27.6	85.9±20.3	98.8±30.0	102.0±23.4	104.1±19.7
Serum triglycerides (mg/dL)	119.9±37.0	158.6±55.9	132.9±66.1	177 ± 134.7	128.3±82.8	186.3±66.8	126.5±56.5	145.4±51.6
Albumin : creatinine ratio (mg/g)	12.2±7.1	120.5 ± 70.7^e	10.0±3.6	82.6 ± 41.9^f	8.8±1.6	86.1±47.1^g	9.8±6.9	107.4±69.4 ^h
Pooled urine concentration (mg/mL)	3.7±1.6	6.9±3.4	4.1±1.2	8.1±4.2	4.7±1.2	7.6±3.8	4.3±1.8	7.1±4.5

^a–cSample sets for the three iTRAQ experiments, ^dsample sets for 2-DE, ^e𝑃<0.001 for NA1 versus MA1, ^f𝑃<0.001 for NA2 versus MA2, ^g𝑃<0.05 for NA3 versus MA3, and ^h𝑃<0.001 for NA4 versus MA4. Data are expressed as the mean ± SD.